Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,313.63 +5.50 (+0.10%) Dow
39,875.92 +69.15 (+0.17%) Nasdaq
16,786.68 -8.20 (-0.05%) Bitcoin USD
70,416.88 +3,560.02 (+5.32%) CMC Crypto 200
1,532.48 +43.94 (+2.95%)
Tonix Pharmaceuticals Holding Corp. (TNXP)
- GlobeNewswire
Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya™ for the Management of Fibromyalgia
Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from two Phase 3 trials Primary physician research found high level of interest in Tonmya as a potential new treatment option for fibromyalgia Significant dissatisfaction reported with drugs currently approved by FDA for the treatment of fibromyalgia Analysis of claims data revealed that addictive opioids are prescribed more frequently tha
- GlobeNewswire
Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
CHATHAM, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.’s Healthcare Company Showcase on Tuesday, May 21, 2024, at 9:00 a.m. ET. A live webcast of the presentation can be found here. A replay of the p
- GlobeNewswire
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights
On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second quarter 2024 Commercial planning continues for U.S. launch of Tonmya, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia CHATHAM, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipel
